Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70450 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Meng Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China. Hauptthemen laut MEDLINE: TYK2 Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
D‐2570 selectively binds to the pseudokinase domain of tyrosine kinase 2, which mediates the downstream cytokine signaling pathways involved in immune regulation. The safety, tolerability, pharmacokinetics, and pharmacodynamics of D‐2570 were evaluated in a randomized, double‐blind, placebo‐controlled phase I study conducted in healthy Chinese subjects. The study consisted of three parts: single ascending dose (D‐2570: 3–48 mg once daily) study, multiple ascending dose (D‐2570: 6–36 mg once daily for 10 days) study, and food effect (D‐2570: 9 mg) study. D‐2570 was rapidly absorbed, with peak plasma concentration at around 4 h and exposure increased sub‐proportional across the dose groups. Following multiple dosing, mean terminal elimination half‐lives at steady state ranged from 22.22 to 33.86 h, with modest area under curve accumulation (1.74‐ to 2.08‐fold) showing no dose dependence. A high‐fat meal increased area under the concentration time curve from time zero extrapolated to infinite time and maximum plasma concentration by 33% and 15% for the 9‐mg dose, with no significant effect on median time to maximum concentration. The inhibitory effect of D‐2570 on the release of interferon‐gamma induced by interleukin‐12/interleukin‐18 increased dose‐dependently in the range of 6–36 mg. No deaths or serious treatment‐emergent adverse events occurred, and all the adverse events were Grade 1 or 2 in severity. D‐2570 was well tolerated in healthy Chinese subjects, and its pharmacokinetic profile was characterized. These results provide the rationale for dose selection in future clinical trials and support advancing D‐2570 as a potential treatment option for autoimmune diseases mediated by tyrosine kinase 2. Trial Registration: Chinadrugtrials.org.cn (CTR20222168)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
- InventisBio Co., Ltd., Shanghai, People's Republic of China.
ORCID-Profile: Meng Wang, Quanying Zhang, Jie Pan
Zitieren
APA
Wang, M., Zhang, Q., Shi, Z., Zhang, L., & Pan, J. (2026). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70450
Vancouver
Wang M, Zhang Q, Shi Z, Zhang L, Pan J. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study. Clinical and Translational Science. 2026. doi:10.1111/cts.70450
BibTeX
@article{Wang2026,
author = {Wang, Meng and Zhang, Quanying and Shi, Zhe and Zhang, Ling and Pan, Jie},
title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70450}
}
EUVIMED